- Conditions
- Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
- Interventions
- Pharmacist-led deprescribing intervention
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pneumonia, Respiratory Failure
- Interventions
- Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colorectal Cancer
- Interventions
- Decision Aid, Provider Education, Performance Measure Modification, Simple Informational Booklet
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 70 Years to 75 Years
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
- Interventions
- Neratinib Oral Tablet, Ruxolitinib Oral Tablet
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Arm A, Arm B
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Winston-Salem, North Carolina
- Conditions
- Pregnancy, Diabetes
- Interventions
- Group Care
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- Quinacrine and Capecitabine
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 12
- States / cities
- Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
- Conditions
- Multiple Chronic Conditions
- Interventions
- Patient Priorities Care
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 66 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Lakewood, Ohio
- Conditions
- Cancer
- Interventions
- TAK-285 Dose Escalation Cohorts, TAK-285 Recommended Phase 2 Dosing Cohort
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan
- Conditions
- Thrombocytopenia
- Interventions
- Computer electronic health record alert (Best Practice Alert - BPA)
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Bone Mineral Density (DEXA) scan, Vitamin D Measurement, Height measurement, Assessment of medication compliance
- Diagnostic Test · Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 5 Years to 12 Years
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Mental Health Issue, Depression, Anxiety
- Interventions
- VIOME Precision Nutrition Program
- Combination Product
- Lead sponsor
- Viome
- Industry
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Bothell, Washington
- Conditions
- Dementia, Alzheimer Type
- Interventions
- ABC Clinical Program, BCN
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment, Lifestyle Counseling, Semaglutide
- Procedure · Other · Behavioral + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 46 Years to 55 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Interventions
- ASTX727
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 21
- States / cities
- Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more
- Conditions
- Kidney Stones
- Interventions
- Patient Navigation
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Lung Cancer, Dyspnea
- Interventions
- Dyspnea Intervention, Enhanced Usual Care
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Coral Gables, Florida • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Metastatic Breast Cancer, Unresectable Breast Cancer
- Interventions
- DiviTum® TKa assay, CDK4/6 + Endocrine therapy
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Heart Failure, Heart Failure, Systolic
- Interventions
- Pharmacist/Cardiologist Virtual Team Digital Consultation
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer, Arthralgia
- Interventions
- Education and exercise intervention, Education and General Exercise
- Behavioral
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Low Back Pain
- Interventions
- Pain EASE, Tailored exercise, Continued Care and Active Monitoring, Cognitive Behavioral Therapy (CBT), Spinal Manipulation Therapy (SMT), Yoga
- Other · Procedure · Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 2,529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Loma Linda, California • Long Beach, California + 16 more
- Conditions
- Sudden Infant Death, Sudden Unexplained Infant Death
- Interventions
- ISA-MI, Standard of Care (SOC)
- Behavioral · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 3 Days to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- pertuzumab, cetuximab, irinotecan hydrochloride, immunohistochemistry staining method, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts